South Wales, Nov. 7 -- United Kingdom Intellectual Property Office (UKIPO) has registered trademark "HARNESSING NEXT-GENERATION SIRNA ENGINEERING" on March 27. The details about the trademark application no. UK00004180197 published in the journal no. 2025/044 (Oct. 31).
With Howard Kennedy LLP as representative, City Therapeutics, Inc. filed the trademark application for the below mentioned good(s)/service(s).
Class 5 : Pharmaceutical preparations; Pharmaceutical preparations, including nucleic acid therapeutics for use in the treatment of diseases and disorders, including genetic, neurologic, gastrointestinal, metabolic, immunological, cardiovascular, ocular, and oncological and diseases of the retina, liver, heart, lung, bone marrow, brain, muscle, immune system and kidneys; Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of diseases and disorders, including genetic, neurologic, gastrointestinal, metabolic, immunological, cardiovascular, ocular, and oncological and diseases of the retina, liver, heart, lung, bone marrow, brain, muscle, immune system and kidneys.
Class 42 : Scientific research; Scientific research in the fields of pharmaceuticals and medicine; Providing scientific information in the field of pharmaceuticals and medicine; Product development for others in the field of pharmaceuticals and medicine.
The original document can be viewed at: http://www.ipo.gov.uk/cgi-bin/redirect.cgi?type=tmj&link=6¶m1=UK00004180197
Disclaimer: Curated by HT Syndication.
